Contact Details
Georgina completed her Honours at The University of Adelaide working on developing novel therapies for the adverse side effects of chemotherapy on the gastrointestinal tract. She then worked at the Children’s Cancer Institute in Sydney for 4 years where she assisted in discovering new therapeutic approaches for the treatment of Neuroblastoma (most common extracranial solid tumour in children). During her time at the Children’s Cancer Institute she was involved in the Zero Childhood Cancer national clinical trial. This trial aims to develop personalised cancer treatment strategies for children, throughout Australia, with high-risk or relapsed cancer.
In mid-2018, Georgina returned to Adelaide to work as an EMBL Australia Research Officer in David Lynn’s Infection & Immunity group at SAHMRI, assisting in projects investigating the interplay between the microbiota and the immune system. Georgina is now the Lab Manager for this group and continues to support and contribute to the lab’s success.
|
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma growth and sensitises to irinotecan in vivo. Eur J Cancer, 2017 Sep; 83:132-141. |
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma growth and sensitises to irinotecan in vivo. |
|
Rhubarb extract partially improves mucosal integrity in chemotherapy-induced mucositis. World J Gastroenterol, 2016 Oct 7; 22(37):8322-8333. |
Rhubarb extract partially improves mucosal integrity in chemotherapy-induced mucositis. |
|
Emu oil combined with Lyprinol™ reduces small intestinal damage in a rat model of chemotherapy-induced mucositis. Nutr Cancer, 2016 Oct; 68(7);1171. |
Emu oil combined with Lyprinol™ reduces small intestinal damage in a rat model of chemotherapy-induced mucositis. |